← Leaderboards
Minyi Gu
Dupage Medical Technology, Inc.
$1,958,173
Attributed
$1,958,173
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $825K · FY2017–19$1M$750K$500K$250K$0
'17
'18
'19
Funding mix
By agency
NIH$1,958,173 · 1
By mechanism
N01$1,958,173 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Animals”
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ted Ross · University Of Georgia$70,992,558
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,986,959
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$49,241,299
Research focus
AnimalsAortic AneurysmAreaClinical TrialsCoronary ArteriosclerosisDissectionDrug ProductionFibrinolytic AgentsGenerationsInhibitor/AntagonistIntegrinsInterestIntracranial ArteryLymphatic DiseasesLymphatic SystemMedical TechnologyPeripheral Arterial DiseasePharmaceutical PreparationsProduct DevelopmentProgramsPulmonary HypertensionPulmonary Vascular DisorderScale UpSignal Transduction
Grant awards (3)
IGF::OT::IGF DEVELOPING AN INHIBITOR OF INTEGRIN OUTSIDE-IN SIGNALING AS A NEW GENERATION OF ANTI-THROMBOTIC DRUG$341,116
N01 · FY2019 · HL · contact PI
DEVELOPING AN INHIBITOR OF INTEGRIN OUTSIDE-IN SIGNALING AS A NEW GENERATION OF ANTI-THROMBOTIC DRUG - VITA 2$825,010
N01 · FY2018 · HL · contact PI
IGF::OT::IGF DEVELOPING AN INHIBITOR OF INTEGRIN OUTSIDE-IN SIGNALING AS A NEW GENERATION OF ANTI-THROMBOTIC DRUG$792,047
N01 · FY2017 · HL · contact PI